Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 2011

View Archived Issues

Phase I trials assess efatutazone in Japanese and Korean patients with advanced solid tumors

Studies provide overview of data on novel antibacterial LFF-571

Posiphen's mechanism of action confirmed in various models

Depomed releases topline data from BREEZE 3 trial of Serada in menopausal hot flashes

Cylene Pharmaceuticals advances CX-5461

FOB Synthesis describes new carbapenem with activity against multidrug-resistant bacteria

New clinical data presented on novel HIV integrase inhibitor

Gene therapy for hemophilia B evaluated in rhesus macaques

Novel lactam acetamides patented by Abbot Laboratories

Catabasis Pharmaceuticals reports novel NF-kappa-B activation inhibitors

Purdue Research Foundation discovers new chemokine CCR5 receptor antagonists

New beta-secretase 1 inhibitors synthesized at Amgen

Dana-Farber Cancer Institute claims new protein kinase inhibitors

Achillion selects clinical candidate from NS5A inhibitor program

Helix BioPharma files clinical hold response with FDA for topical interferon alfa-2b

FDA continues clinical hold on Insmed's study of Arikace in NTM lung disease

Merck & Co. terminates JTT-305 licensing agreement

Mitsubishi Tanabe Pharma gains North American rights to TRK-820

Eisai and Johns Hopkins University enter collaboration

Azelon raises funds to support development of nasal spray for osteoporosis

Ongoing trial assesses modafinil in postoperative cognitive dysfunction

Medgenics and Baxter discuss continuation of Biopump collaboration

Epizyme triggers milestone payment in HMT therapeutic alliance with GSK

Teva Pharmaceutical acquires Cephalon

Migalastat hydrochloride evaluated in female patients with Fabry's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...